FLUENCE-TECHNOLOGIES
5.7.2022 14:47:05 CEST | Business Wire | Press release
Fluence Technologies , the only provider of purpose-built financial consolidation, close and reporting software for high-growth businesses, today announced the acquisition of Sturnis365, the leading provider of intelligent, collaborative disclosure management and narrative reporting solutions.
Sturnis365 serves dozens of public, private and pre-IPO customers across Europe including AB InBev, Enel Group, Rothschild & Co., Bouygues Group, Ferragamo and KBC Bank. Like Fluence, Sturnis365 offers a familiar Microsoft Office interface and domain-specific workflow to automate collaborative report production, combining companywide data and narrative text for:
- Immediate adoption among finance and business professionals compared to reporting available in their ERP system
- Game-changing efficiency gains in report production compared to standalone Excel spreadsheets, Word and PowerPoint documents
- Trusted, accurate internal and external reporting for any stakeholder, auditor or regulator
“Sturnis365 is a natural extension of our consolidation, close and reporting solution so CFOs can stay ahead of evolving reporting demands on the office of finance,” said Michael Morrison, CEO of Fluence Technologies. “Further, Sturnis365 strengthens our position in Europe, where more than 70% of their customers and partners are based. We also gain seasoned employees with strong ‘DNA’ in collaborative disclosure management.”
“We are excited about the value Fluence and Sturnis365 presents to our customers and partners,” said Didier Katz, co-founder and director at Sturnis365. “Companies across the globe are looking for a solution that combines financial consolidation, close and disclosure management in a single offering. Now, Fluence is the only player on the market that can meet this need."
Katz and fellow Sturnis365 co-founders Marco Mattei and Piero Ferreri are joining Fluence’s leadership team as part of the acquisition, along with their respective teams in product development, services, sales and marketing.
Fluence and Sturnis365 have already secured joint customers including cryptocurrency trading platform provider WonderFi.
“When we learned about Sturnis365, we were considering a legacy disclosure management solution that would have cost a significant amount and taken months to implement,” said John Rim, CFO at WonderFi. “Between its out-of-the-box functionality, Office integration and the fact that our finance team can manage the entire reporting process, we quickly realized how much more we’d benefit from Sturnis365.”
“Today’s CFOs don’t just need modern consolidation software, but end-to-end group accounting solutions spanning from account reconciliation to disclosure management.” said Carsten Bange, founder and CEO of BARC. “With its acquisition of Sturnis365, Fluence has broadened its offering to meet the changing needs of the constantly evolving finance function.”
"Acquiring Sturnis365 continues building on the vision of a complete financial corporate performance management suite that Michael Morrison and our team had when we originally invested in Fluence,” said Stephen Davis, managing partner at Banneker Partners, Fluence’s principal investor. “We look forward to Fluence continuing to deliver exceptional value to its customers."
The announcement comes just over six months after Fluence acquired self-serve, Excel-centric reporting software vendor XLCubed, and three months after unveiling its purpose-built account reconciliation and transaction matching solution. As a result, Fluence now has the market’s only end-to-end consolidation, close and reporting solution, and over 900 customers worldwide.
For more information on Fluence’s disclosure management and narrative reporting solution, visit: https://www.fluencetech.com/disclosuremanagement/home
About Fluence Technologies - www.fluencetech.com
Fluence is the only pure-play financial consolidation, close and reporting software for high growth businesses. Our customers go live in weeks, close their books in days and report intelligence in real time. We deliver game-changing efficiency gains and trusted, timely numbers to over 900 customers so they get the time, control and confidence they deserve. Fluence is out-of-the-box, no-coding software with a full Excel interface and enterprise-grade capabilities for immediate adoption and quick time to value, all in a truly finance-owned solution. Welcome to Fluence...we close early.
About Sturnis365 - www.sturnis365.com
Sturnis365 provides full end-user collaborative creation, publication and disclosure of corporate information, including for annual and periodical corporate reports, sustainability and ESG reporting, compliance and risk reporting and procurement and tax disclosures. Our unique Inversed Design capability allows for automated data synchronization to reduce document setup and maintenance and optimize overall cost of ownership.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005268/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
